Article: Geron Receives Favorable Ruling in Nuclear Transfer Patent Interference: Opponent's Patent Claims Are Found Unpatentable, Geron's Patent Claims Are Upheld.

Business Editors/Health/Medical Writers

BIOWIRE2K

MENLO PARK, Calif.--(BUSINESS WIRE)--March 18, 2004

Geron Corporation (Nasdaq:GERN) announced today that the Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office has issued a decision on motions filed in the patent interference proceeding between Geron and Advanced Cell Technology Corporation of Worcester, Mass. ("ACT"). The decision finds all claims in the issued ACT nuclear transfer patent to be unpatentable. All motions filed by ACT were denied, including motions attacking the patentability of Geron's claims.

This proceeding is one of two interferences ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!